<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Adnexal mass: Evaluation and management in pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Adnexal mass: Evaluation and management in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Adnexal mass: Evaluation and management in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carolyn D Runowicz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Molly Brewer, DVM, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The liberal use of prenatal ultrasound for evaluation of the fetus has also resulted in increased detection of asymptomatic adnexal masses during pregnancy. Although the vast majority of these masses are benign, the possibility of cancer must be considered.</p><p>This topic will discuss management of the adnexal mass in pregnancy, with an emphasis on patients with suspected malignancy. Detailed reviews on the evaluation and management of the nonpregnant patient with an adnexal mass can be found separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>The incidence of adnexal masses complicating pregnancy varies from 0.05 to 2.4 percent, and approximately 1 to 6 percent of these masses are malignant [<a href="#rid1">1-4</a>]. A review of publications on ovarian cancer during pregnancy from 1958 to 2007 included 41 cases [<a href="#rid5">5</a>]. The mean age at presentation was 32.6 years (range 23 to 46 years); stage at diagnosis was recorded in 39 cases: International Federation of Gynecology and Obstetrics (FIGO) I (59 percent), FIGO II (5 percent), FIGO III (26 percent), and FIGO IV (10 percent). It is important to remember that the use of obstetric ultrasound and cesarean birth were much less common in the initial decades of this interval, thus there was less opportunity for incidental detection of asymptomatic adnexal masses.</p><p>In a population-based hospital registry series of malignancies identified during pregnancy using birth records linked to hospital discharge data (1992 to 1997), ovarian cancer was the fifth most common cancer diagnosed during pregnancy after breast, thyroid, cervical cancer, and Hodgkin lymphoma [<a href="#rid2">2,6</a>]. There was also a high proportion of tumors of low malignant potential (n = 115) reported separately, with the majority in early stage and associated with favorable maternal and neonatal outcomes. A retrospective review reported that ovarian cancer was the sixth most common cancer in patients from Korea [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATIENT PRESENTATION</span><span class="headingEndMark"> — </span>Prior to the widespread use of ultrasound, most adnexal masses in pregnant patients remained unrecognized until cesarean birth or until they became symptomatic, usually in the postpartum period. Now many asymptomatic masses are recognized in the first half of pregnancy when they are identified incidentally during an antenatal ultrasound performed for obstetric indications [<a href="#rid1">1,5,7,8</a>]. Adnexal masses that have not been diagnosed antepartum may be identified at cesarean birth. In a retrospective study of over 46,500 term cesarean deliveries performed for obstetric indications, 151 patients (0.3 percent) underwent concurrent surgery of an adnexal mass, which was an incidental finding at surgery in just over half of the patients (83 of 151; 55 percent) [<a href="#rid9">9</a>].</p><p>Other clinical presentations include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonspecific symptoms</strong> – Symptoms and signs that precede the diagnosis of ovarian cancer include abdominal or back pain, constipation, abdominal swelling, and urinary symptoms [<a href="#rid10">10,11</a>]. Since these symptoms are almost universally present in normal pregnancies, their presence is unlikely to trigger a diagnostic evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palpable mass</strong> – In some patients, a suspicious finding, such as a palpable adnexal mass or posterior cul-de-sac mass or nodularity, may be identified during a routine antenatal physical examination and subsequently evaluated by ultrasound.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute abdominal pain</strong> – In a few patients, acute abdominal pain due to torsion of the adnexa prompts the diagnostic evaluation. Adnexal torsion occurs in approximately 5 percent of pregnant patients with an adnexal mass (benign or malignant) [<a href="#rid1">1</a>]. In one review, adnexal masses between 6 and 8 cm in diameter had a significantly higher rate of torsion (22 percent) than either smaller or larger masses [<a href="#rid12">12</a>]. Sixty percent of the torsions occurred between the 10th and 17th week of gestation; only 6 percent occurred after 20 weeks. (See  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated maternal analytes</strong> – Many germ cell and sex cord-stromal tumors of the ovary produce hormonal tumor markers, some of which are measured in prenatal screening programs for fetal abnormalities (eg, alpha-fetoprotein [AFP], inhibin A)  (<a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. An unexplained elevation in these maternal serum analytes, obtained while screening for neural tube defects or Down syndrome, may be the first sign of one of these tumors [<a href="#rid13">13</a>]. (See <a class="local">'Tumor markers in ovarian malignancy'</a> below.)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">TYPES OF ADNEXAL MASSES IN PREGNANT PATIENTS</span><span class="headingEndMark"> — </span>In a review of seven studies, there were 563 adnexal masses in 557 patients. Of these, 48 percent were classified as simple and 53 percent as complex. Among the simple masses, 1 percent were malignant whereas in the complex masses, 9 percent were malignant [<a href="#rid3">3</a>]. In another retrospective study of 151 patients who underwent surgery of an adnexal mass at cesarean birth, the adnexal mass was benign in 148 cases. Histopathologies accounting for over 4 percent of cases in the series included dermoid (24 percent), paratubal/paraovarian (19 percent), simple serous (15 percent), mucinous cystadenoma (11 percent), serous cystadenoma (7 percent), corpus luteum (5 percent), endometrioma (5 percent), and fibroma (5 percent) [<a href="#rid9">9</a>]. The three malignancies in the series consisted of two granulosa cell tumors and one mucinous carcinoma.</p><p class="headingAnchor" id="H11"><span class="h2">Benign neoplasms</span><span class="headingEndMark"> — </span>Most adnexal masses identified in pregnant patients are benign simple cysts less than 5 cm in diameter. Most of these are functional ovarian cysts, either follicular or corpus luteum cysts, that occur as part of the normal physiological function of the ovary. Approximately 70 percent of all adnexal cystic masses detected in the first trimester spontaneously resolve by the early part of the second trimester, which is consistent with the natural history of functional cysts [<a href="#rid7">7</a>]. The majority of persistent adnexal masses 5 cm or greater in diameter are mature teratomas [<a href="#rid1">1</a>].</p><p>The differential diagnosis of the adnexal mass is reviewed in detail separately (see  <a class="medical medical_review" href="/z/d/html/3204.html" rel="external">"Adnexal mass: Differential diagnosis"</a>). Briefly, benign adnexal masses are characterized by their ultrasonographic appearance and, in some cases, associated clinical findings (see  <a class="medical medical_review" href="/z/d/html/3208.html" rel="external">"Adnexal mass: Ultrasound categorization"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Benign masses without complex features on ultrasound are generally physiologic/functional cysts (eg, follicular cysts), but may be unilocular serous or mucinous cystadenoma or hydrosalpinx. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benign masses with complex features on ultrasound include corpus luteum, mature teratomas, hydrosalpinx with septation, theca lutein cysts, endometriomas, multilocular cystadenomas, as well as extrauterine pregnancies [<a href="#rid14">14</a>]. The corpus luteum persists longer during pregnancy and thus is likely to reach a larger size and may become hemorrhagic, rupture, or undergo torsion.</p><p></p><p class="bulletIndent1">Theca lutein cysts (also called lutein cysts, hyperreactio luteinalis) are luteinized follicle cysts that form as a result of overstimulation from high human chorionic gonadotropin (hCG) levels or hypersensitivity to hCG. Bilateral multiseptated cystic adnexal masses in a patient with gestational trophoblastic disease, multiple gestation, ovulation induction, or a pregnancy complicated by fetal hydrops are likely to represent theca lutein cysts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A luteoma is an uncommon solid benign lesion specific to pregnancy. It is a non-neoplastic ovarian change associated with pregnancy that can simulate a neoplasm on clinical, gross, or microscopic examination. The diagnosis should be suspected when a solid adnexal mass is associated with maternal hirsutism or virilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncomplicated pedunculated leiomyomas are usually hypoechoic compared with normal myometrium, but may have a complex appearance when there is necrosis or degeneration.</p><p></p><p>The presence of pain should suggest the possibility of heterotopic pregnancy, torsion or rupture of an ovarian neoplasm, or degeneration of a leiomyoma. (See  <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">"Ectopic pregnancy: Clinical manifestations and diagnosis", section on 'Heterotopic pregnancy'</a> and  <a class="medical medical_review" href="/z/d/html/3305.html" rel="external">"Ovarian and fallopian tube torsion"</a> and  <a class="medical medical_review" href="/z/d/html/3298.html" rel="external">"Evaluation and management of ruptured ovarian cyst"</a> and  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history", section on 'Fibroid degeneration or torsion'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Malignant neoplasms</span><span class="headingEndMark"> — </span>Epithelial ovarian tumors comprise approximately one-half of all ovarian malignancies in pregnant patients, germ cell ovarian malignancies make up approximately one-third, and stromal tumors and a variety of other tumor types (eg, sarcomas, metastatic tumors) account for the remainder  (<a class="graphic graphic_figure graphicRef57398" href="/z/d/graphic/57398.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H14"><span class="h3">Epithelial ovarian tumors</span><span class="headingEndMark"> — </span>Approximately 50 percent of epithelial ovarian tumors detected in pregnancy are of low malignant potential (formerly called "borderline"), and the other 50 percent are invasive. Epithelial ovarian tumors of low malignant potential diagnosed in pregnancy may exhibit atypical characteristics suggestive of invasive cancer such as nuclear enlargement, anisocytosis, and multifocal microinvasion. (See  <a class="medical medical_review" href="/z/d/html/3181.html" rel="external">"Borderline ovarian tumors"</a> and  <a class="medical medical_review" href="/z/d/html/3238.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Germ cell tumors</span><span class="headingEndMark"> — </span>Approximately three-fourths of malignant ovarian germ cell tumors in pregnancy are dysgerminomas; endodermal sinus tumors, immature teratomas, and mixed germ cell tumors comprise the remainder [<a href="#rid15">15</a>]. Most germ cell tumors are grossly limited to one adnexa, but lymphatic spread to pelvic or para-aortic nodes occurs, most commonly in dysgerminoma [<a href="#rid16">16</a>]. Dysgerminomas are bilateral in 10 to 15 percent of cases; other germ cell tumors are almost always unilateral. (See  <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Sex cord-stromal tumors</span><span class="headingEndMark"> — </span>Approximately half of all pregnancy-associated stromal tumors are granulosa cell tumors, one-third are Sertoli-Leydig cell tumors, and the remainder are unclassified stromal tumors [<a href="#rid17">17</a>]. Most of these tumors are limited to one ovary at the time of diagnosis. Prior to the routine use of prenatal ultrasound, approximately 20 percent of these lesions presented with intraperitoneal hemorrhage and/or hemorrhagic shock, but this has become less common with earlier diagnosis.</p><p>Between 10 and 15 percent of stromal tumors secrete androgens and produce virilization. Although estrogen secretion also occurs, symptoms of a hyperestrogenic state are masked by the already high estrogen concentration associated with pregnancy.</p><p>Pregnancy-related histologic changes in these tumors include a disorderly arrangement of cells, increased edema, and unusually large numbers of lutein or Leydig cells [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H189801094"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Definitive diagnosis can only be made by resecting the ovarian neoplasm for pathologic examination. However, some benign ovarian masses, including follicular or corpus luteal cysts, endometriomas, and mature teratomas (dermoid), have characteristic sonographic features, and the diagnosis is reasonably certain without surgical exploration. </p><p>It is important that ovarian tissue is examined by a pathologist skilled in interpretation of histologic findings in the context of an ongoing pregnancy and that the pathologist is informed of the coexistent pregnancy. Pregnancy-related changes in the histologic appearance of tumors of low malignant potential can result in atypical characteristics suggestive of invasive cancer. In one series, 8 of 10 serous neoplasms diagnosed in pregnancy had microscopic and clinical features suggesting aggressive behavior; however, all of these features regressed postpartum in this small series, confirming that the neoplasms were of low malignant potential [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H514904646"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H189801839"><span class="h2">Patient selection for surgery</span><span class="headingEndMark"> — </span>The general consensus regarding management of adnexal masses in pregnancy is to surgically resect asymptomatic masses that are present after the first trimester and (1) are &gt;10 cm in diameter or (2) are solid or contain solid and cystic areas or have papillary areas or septae [<a href="#rid1">1,4,12,19-23</a>]. The rationale for this approach is that these findings increase the likelihood of malignancy, and it is desirable to diagnose malignancy, if present, at an early stage. In addition, resection of large adnexal masses (benign or malignant) reduces the risk of complications such as adnexal torsion, rupture, or obstruction of labor [<a href="#rid24">24</a>]. Emergency surgery during pregnancy for management of a torsed or ruptured adnexal mass is uncommon (&lt;5 percent of cases [<a href="#rid1">1,25</a>]) and can lead to preterm delivery [<a href="#rid19">19,20,26</a>].</p><p>Adnexal masses that do not have concerning features (eg, persistence into the second trimester, large size, or solid components) are likely to be physiologic cysts and can be managed expectantly [<a href="#rid1">1,24,27-33</a>], and often resolve during pregnancy. Expectant management is also appropriate for cysts with these features if the sonographer is reasonably certain that the neoplasm is a follicular or corpus luteal cyst, endometrioma, or mature teratoma. Surgical treatment of endometriomas depends upon whether the patient is symptomatic. Most mature teratomas are benign, but surgery may be indicated postpartum to prevent torsion (see  <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis", section on 'Mature cystic teratomas'</a>). For any ovarian mass, if the diagnosis is uncertain, further evaluation is required. Up to 10 percent of adnexal masses that persist during pregnancy are malignant [<a href="#rid4">4,28,34</a>]. A substantial portion of these are epithelial low malignant potential tumors or germ cell tumors, both tumors with a typically favorable prognosis. (See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass", section on 'Other high-risk premenopausal patients'</a>.)</p><p class="headingAnchor" id="H189802027"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The optimal time for semi-elective surgery during pregnancy is after the first trimester for a number of reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Almost all functional cysts will have resolved by this time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organogenesis is mostly complete, thus minimizing the risk of drug-induced teratogenesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hormonal function of the corpus luteum has been replaced by the placenta, so reduction in <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> secretion from oophorectomy or cystectomy does not result in loss of the pregnancy if not replaced.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous pregnancy losses due to intrinsic fetal abnormalities are likely to have already occurred and will not be erroneously attributed to the surgery.</p><p></p><p>Postponing the surgery until after delivery may be performed in select cases [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H189802390"><span class="h2">Preoperative assessment</span><span class="headingEndMark"> — </span>In most cases, the preoperative workup for a pregnant patient with a pelvic mass can be limited to ultrasound imaging [<a href="#rid24">24</a>]. If the ultrasound findings cannot distinguish between a possible pedunculated or degenerating leiomyoma and an ovarian neoplasm, we suggest obtaining magnetic resonance imaging (MRI). The more precise diagnosis afforded by MRI may be useful in opting for expectant management until delivery [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/3208.html" rel="external">"Adnexal mass: Ultrasound categorization"</a>.)</p><p>A routine preoperative chest radiograph is unnecessary; however, if the history and physical examination suggest pulmonary disease, then a chest radiograph should be obtained with shielding of the abdomen/pelvis.</p><p class="headingAnchor" id="H514905845"><span class="h3">Secondary imaging</span><span class="headingEndMark"> — </span>In most cases, ultrasound examination provides sufficient information to guide a decision for exploratory surgery versus conservative, expectant management, but occasionally, further radiologic evaluation is required. MRI has excellent resolution for soft tissue pathology and does not expose the patient (or fetus) to ionizing radiation. Therefore, MRI is particularly useful in characterizing a pedunculated leiomyoma, red degeneration of leiomyomas, endometriomas, decidualized endometriomas, and massive ovarian edema and distinguishing these lesions from ovarian cancer [<a href="#rid36">36,37</a>]. Gadolinium-based contrast material should generally be avoided in pregnancy because fetal safety has not been established. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients", section on 'Use of iodinated contrast materials'</a>.)</p><p>Computed tomography (CT) is avoided in pregnant patients if other imaging methods can provide the needed information [<a href="#rid35">35</a>]. The fetal ionizing radiation dose for a single CT through the pelvis is 0.035 Gy. Although fetal radiation exposure of less than 0.05 Gy has not been associated with an increased risk of abortion, congenital anomalies, growth restriction, or perinatal mortality, there remain concerns regarding a possible increase in the risk of developing childhood cancer [<a href="#rid38">38,39</a>]. In addition, the use of iodinated contrast agents with CT carries a risk of transient suppression of the fetal thyroid. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p class="headingAnchor" id="H514905278"><span class="h3">Tumor markers in ovarian malignancy</span><span class="headingEndMark"> — </span>Although serum tumor markers are routinely drawn preoperatively when planning a laparotomy for management of a pelvic mass in nonpregnant patients, we do not suggest this approach during pregnancy. Pregnancy-associated pelvic masses are infrequently malignant, and the interpretation of these tumor markers varies with gestational age and comorbid conditions. If a malignancy is proven, then appropriate tumor markers may be drawn in the immediate postoperative period.</p><p>Several of the tumor markers used to follow epithelial and nonepithelial ovarian cancers in nonpregnant patients  (<a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">table 1</a>) are difficult to interpret in pregnancy because oncofetal antigens (eg, alpha-fetoprotein [AFP], human chorionic gonadotropin [hCG], carcinoembryonic antigen [CEA], cancer antigen 125 [CA 125]) are involved in biological functions associated with fetal development, differentiation, and maturation. The levels are normally elevated during gestation and fluctuate with gestational age, or they may be abnormally elevated due to abnormal placentation or fetal abnormalities (eg, preeclampsia, Down syndrome, open neural tube defect) [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H514905333"><span class="h4">Serum CA 125</span><span class="headingEndMark"> — </span>Serum levels of CA 125 are elevated in most cases of epithelial ovarian cancer (EOC). CA 125 is also produced by normal tissues, including endometrium, and may be elevated during early gestation and immediately following delivery  (<a class="graphic graphic_table graphicRef81621" href="/z/d/graphic/81621.html" rel="external">table 2</a>) [<a href="#rid13">13</a>]. However, CA 125 may be helpful as a tumor marker of EOC between 15 weeks of gestation and delivery, as serum values at this time are unlikely to be markedly elevated solely as a consequence of pregnancy. A CA 125 in the range of 1000 to 10,000 is likely (but not invariably) related to cancer, but values in the range of 75 to 150 could be either pregnancy-related or due to an ovarian cancer that does not demonstrate high expression of CA 125.</p><p class="headingAnchor" id="H514905339"><span class="h4">Alpha-fetoprotein</span><span class="headingEndMark"> — </span>Maternal serum levels of AFP (MSAFP) normally rise during pregnancy; serum levels are routinely assayed as part of the screen for fetal neural tube defects and Down syndrome. High MSAFP levels are seen in some types of ovarian germ cell tumors (eg, endodermal sinus tumor, embryonal carcinoma, and mixed tumors). These levels are often &gt;1000 ng/mL, especially with pure endodermal sinus (yolk sac) tumors, which can be associated with levels &gt;10,000 ng/mL [<a href="#rid40">40,41</a>]. By comparison, MSAFP levels are typically &lt;500 ng/mL in pregnancies complicated by neural tube defects. (See  <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>During pregnancy, AFP results are typically expressed as multiples of the median (MoM) for each gestational week because these values are easy to derive, more stable, and allow for inter-laboratory variation. MSAFP levels that are above 2.0 to 2.5 MoMs are considered abnormal. The AFP levels associated with ovarian cancer typically translate into much higher MoM values than seen with neural tube defects. In one case report, a MSAFP of 26,300 ng/mL translated into a MoM value of 24 [<a href="#rid42">42</a>]; in another, a level of 477.8 int. unit/mL (370 ng/mL) translated into a MoM of 12.5 [<a href="#rid43">43</a>]. Some authors suggest that a MSAFP level above 9 MoM should prompt concern for germ cell tumors of either gonadal or nongonadal origin in the absence of fetal abdominal wall defects or anencephaly [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/460.html" rel="external">"Neural tube defects: Overview of prenatal screening, evaluation, and pregnancy management"</a> and  <a class="medical medical_review" href="/z/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues"</a>.)</p><p class="headingAnchor" id="H514905345"><span class="h4">Lactate dehydrogenase</span><span class="headingEndMark"> — </span>Serum lactate dehydrogenase (LDH) is elevated in the serum of patients with ovarian dysgerminomas and is a reliable marker for diagnosis and follow-up of these tumors in pregnant patients [<a href="#rid44">44</a>]. LDH is not elevated in normal pregnancy, although elevations can occur in some pregnancy-related disorders such as preeclampsia and HELLP syndrome (Hemolysis, Elevated Liver function tests, Low Platelets) [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis", section on 'Dysgerminoma'</a> and  <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p class="headingAnchor" id="H514905351"><span class="h4">Inhibin A</span><span class="headingEndMark"> — </span>Although serum inhibin A is a useful tumor marker for following the course of treatment for ovarian granulosa cell tumors in nonpregnant patients, inhibin A is made in the developing placenta, and serum levels are elevated in early gestation [<a href="#rid46">46,47</a>]. This limits the value of inhibin A as a tumor marker during pregnancy. Like AFP, inhibin A levels may be measured as a component of screening for Down syndrome. Inhibin A concentrations are, on average, twofold higher in pregnancies complicated by Down syndrome than in unaffected pregnancies. (See  <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/414.html" rel="external">"Maternal serum marker screening for Down syndrome: Levels and laboratory issues"</a>.)</p><p class="headingAnchor" id="H514905357"><span class="h4">Human chorionic gonadotropin</span><span class="headingEndMark"> — </span>The beta subunit of hCG is a useful marker for some germ cell neoplasms (particularly choriocarcinoma,  (<a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">table 1</a>)). However, it cannot be used as a tumor marker during pregnancy due to the large physiologic increase in this hormone. (See  <a class="medical medical_review" href="/z/d/html/3209.html" rel="external">"Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"</a>.)</p><p class="headingAnchor" id="H514905363"><span class="h4">Human epididymis protein 4 (HE4)</span><span class="headingEndMark"> — </span>Human epididymis protein 4 (HE4) is the product of the <em>WFDC 2</em> (HE4) gene that is overexpressed in ovarian cancer. Assessment of the HE4 level is approved for monitoring patients with ovarian cancer for disease recurrence or progression, but not for screening. In a study of serum samples from 67 pregnant patients without ovarian cancer, median HE4 values were significantly lower in pregnant patients than in healthy, nonpregnant, premenopausal patients (30.5 versus 46.6 pmol/L) [<a href="#rid48">48</a>]. The 95th percentiles for HE4 in pregnant patients in the first, second, and third trimesters were 49.6, 35.1, and 50.2 pmol/L, respectively. Levels were measured using an enzyme immunometric assay (EIA) assay kit from Fujirebio Diagnostics Inc. In another series, higher concentrations of HE4 were detected in pregnant versus nonpregnant serum, but were not statistically significant. The authors concluded that HE4 serum biomarkers are unaffected by pregnancy [<a href="#rid49">49</a>], and therefore may be helpful in the evaluation of pelvic masses in pregnancy.</p><p class="headingAnchor" id="H189802448"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>Issues related to preparation of the pregnant patient for nonobstetric surgery and management of anesthesia in pregnant patients are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy"</a>.)</p><p>Laparoscopy is an acceptable alternative to laparotomy for management of benign adnexal masses in pregnancy [<a href="#rid50">50</a>]. In a meta-analysis of four studies (one was a randomized trial) with a total of 240 patients evaluating laparoscopic versus open surgery for management of adnexal masses in the second trimester, laparoscopy was associated with better surgical outcomes but longer operative times. Of note, the laparoscopic group had smaller ovarian cysts.</p><p>If a malignancy is suspected, a laparotomy should be performed. A Pfannenstiel incision should be avoided, as it would not provide sufficient exposure. The vertical midline incision should be adequate to minimize the need to manipulate the gravid uterus while obtaining exposure to the adnexal mass.</p><p>Immediately after entry into the peritoneal cavity, peritoneal washings should be obtained for staging purposes in case the mass is malignant. The opposite adnexa should be carefully inspected and palpated for a contralateral adnexal mass. Contralateral ovarian biopsy is recommended if the ovary appears to be involved, but routine biopsy or wedge resection of a normal-appearing contralateral ovary is unwarranted.</p><p>The most common findings at surgery are persistent corpus luteal functional cysts, benign dermoid cysts, and serous or mucinous cystadenomas. If the preoperative imaging and intraoperative gross findings are both consistent with a benign diagnosis, it is reasonable to attempt a cystectomy rather than perform a salpingo-oophorectomy. If the mass is larger than 10 cm, it may not be technically feasible to perform an ovarian cystectomy. If the mass is solid, has surface excrescences, is associated with ascites, or has other features suggesting malignancy, then ipsilateral salpingo-oophorectomy is appropriate. The mass should be sent for frozen section and the pathologist informed of the concurrent pregnancy. Resection of the contralateral ovary should not be performed unless bilateral disease is identified; this decision must await the frozen section analysis. All suspicious lesions should be biopsied.</p><p>If the pathologist confirms a malignant tumor at frozen section, the surgeon should be prepared to complete an adequate surgical staging procedure, and a gynecologic oncologist should be consulted. The general principles of the staging procedure for a malignant ovarian tumor are described in the table  (<a class="graphic graphic_table graphicRef75194" href="/z/d/graphic/75194.html" rel="external">table 3</a>) and in detail separately. Obviously, hysterectomy is not performed if preservation of the pregnancy is desired, and the surgeon must individualize each case, weighing the pros and cons of staging versus potential risk to the mother and fetus. In certain malignant germ cell tumors of the ovary (eg, endodermal sinus tumors), lymph node dissection may be omitted, as the patient will require chemotherapy based on the histopathology alone. (See  <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a>.)</p><p>Adequate surgical staging is of particular importance for stage I cancers (ie, those that are limited to the ovary  (<a class="graphic graphic_table graphicRef113545" href="/z/d/graphic/113545.html" rel="external">table 4</a>)), as many, but not all, of these neoplasms are adequately treated with surgery alone. In such cases, the need for postoperative adjuvant chemotherapy is determined by the histologic tumor type. Surgical staging (eg, sampling of lymph nodes) is less critical in the setting of obvious advanced disease (eg, stage IIIB/C disease), as these tumors (with the exception of tumors of low malignant potential) will require chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/3198.html" rel="external">"Chemotherapy of ovarian cancer in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/3197.html" rel="external">"Treatment of malignant germ cell tumors of the ovary"</a> and  <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p>If a metastatic ovarian cancer is identified, cytoreduction should be attempted. The extent of surgical cytoreduction involves individual judgment, balancing the extent of surgery with the expected benefit. It is rare that removal of the gravid uterus is required for maximal cytoreductive surgery at the initial surgery because it is possible, if necessary, to return for secondary cytoreduction following chemotherapy and successful completion of the pregnancy. This management strategy is not thought to adversely impact survival, although as a general rule, survival is poor for patients who have late-stage disease.</p><p>Despite the importance of early surgical debulking to outcomes in ovarian cancer, the surgeon should keep in mind the sensitivity of these tumors to platinum-based chemotherapy when aggressive resection of metastatic disease is considered. With modern platinum-based adjuvant chemotherapy, approximately 70 percent of patients who present with advanced disease will respond to chemotherapy, even if they have residual disease remaining after cytoreductive surgery. </p><p>The hazard of overly aggressive surgery and delay in starting chemotherapy can be illustrated by a case report of a patient with a yolk sac tumor that was resected at 19 weeks of gestation [<a href="#rid51">51</a>]. Chemotherapy was delayed because of the pregnancy and at 32 weeks of gestation, tumor recurrence necessitated a cesarean-hysterectomy and bowel resection with colostomy. Three weeks later, the colostomy was taken down and another suprahepatic tumor mass was resected. The patient was then given <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) for four cycles, but the course was complicated by a fecal fistula that developed at the colostomy site. (See  <a class="medical medical_review" href="/z/d/html/3198.html" rel="external">"Chemotherapy of ovarian cancer in pregnancy"</a>.)</p><p>For patients with advanced-stage ovarian cancer diagnosed before delivery, hysterectomy and secondary cytoreductive surgery are reasonable postpartum to remove persistent disease. This surgery can be performed following vaginal birth or in conjunction with cesarean birth. This approach has been taken by a few investigators who reported managing advanced epithelial ovarian cancer (EOC) cases during pregnancy [<a href="#rid52">52-55</a>]. In four case reports, two patients had persistent disease involving the adnexa [<a href="#rid52">52,53</a>], two cases involved the bowel [<a href="#rid53">53,54</a>], and one case also involved the pelvic peritoneum, omentum, and appendix [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H189802811"><span class="h2">Management of corpus luteum</span><span class="headingEndMark"> — </span>Removal of the corpus luteum should be avoided prior to eight weeks of gestation because the corpus luteum is primarily responsible for <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> production and maintenance of the pregnancy at this time [<a href="#rid56">56</a>]. If the corpus luteum is removed prior to eight weeks, progesterone supplementation should be given as a 50 to 100 mg vaginal suppository every 8 to 12 hours or as a daily intramuscular injection of 1 mL (50 mg) progesterone in oil. After eight weeks, the ovary gradually shifts progesterone production to the placenta (called the luteal-placental shift) [<a href="#rid57">57</a>]. As of 10 weeks of gestation, the placenta is the primary provider of progesterone, so progesterone supplementation is no longer indicated. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy"</a>.)</p><p class="headingAnchor" id="H514905004"><span class="h2">Adnexal mass at cesarean delivery</span><span class="headingEndMark"> — </span>At cesarean birth, any adnexal mass that appears suspicious for malignancy should be removed and sent for frozen section. Complete surgical removal is preferred to aspiration and cytologic evaluation of cystic fluid, since malignancy could be missed with the latter. If the mass is an incidental finding at cesarean birth, the patient typically will not have an appropriate incision for surgical staging. In these cases, if frozen section indicates malignancy, salpingo-oophorectomy is performed and postpartum, the patient is referred to a gynecologic oncologist for counseling, staging, and possible hysterectomy within the next one to two weeks.</p><p>If an adnexal mass suspicious for malignancy is detected antepartum, the patient should be counseled and consented appropriately. Cesarean birth should be performed through a midline incision, and a gynecologic oncologist should be available, if required. After delivery of the infant and placenta and control of bleeding, the adnexal mass is resected and sent for frozen section. If positive for malignancy, full surgical staging can be performed. (See  <a class="medical medical_review" href="/z/d/html/3193.html" rel="external">"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Surgical staging"</a>.)</p><p class="headingAnchor" id="H514906152"><span class="h1">CHEMOTHERAPY</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/3198.html" rel="external">"Chemotherapy of ovarian cancer in pregnancy"</a>.)</p><p class="headingAnchor" id="H189803014"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>As with nonpregnant patients, the prognosis of pregnant patients with ovarian tumors depends on tumor histology, stage, and grade. The majority (approximately 75 percent) of invasive ovarian malignancies in pregnant patients are early-stage disease [<a href="#rid58">58</a>]. Due to the favorable mix of stage, grade, and histology, the five-year survival rate for ovarian tumors associated with pregnancy is between 72 and 91 percent [<a href="#rid59">59,60</a>]. The presence of ascites at diagnosis implies advanced disease and poor prognosis [<a href="#rid59">59</a>].</p><p>Data regarding mortality in pregnant patients are conflicting. In a nationwide cohort study conducted in Sweden from 1970 to 2018 including 5781 patients with ovarian and fallopian tube cancer, those with pregnancy-associated cancers (PAC; patients diagnosed with cancer during pregnancy or within the first year postpartum; 181 patients) compared with non-PACs had similar mortality rates; the median follow-up time was almost seven years [<a href="#rid61">61</a>]. By contrast, one cohort study found that postpartum lactating patients diagnosed with ovarian cancer had a poorer prognosis than patients diagnosed before or during pregnancy; however, the number of cases was small [<a href="#rid62">62</a>]. In a subsequent retrospective study including 764 premenopausal patients with ovarian cancer, those with cancers diagnosed during compared with remote from pregnancy had a greater risk of death (adjusted hazard ratio [aHR] 2.6, 95% CI 1.12-6.03) [<a href="#rid60">60</a>]; the risk of death was similar for those with cancers diagnosed postpartum compared with remote from pregnancy. </p><p>The decision to continue or terminate a pregnancy when ovarian cancer is diagnosed in the first trimester should be individualized and made by a fully informed patient in collaboration with the clinician. Early termination of pregnancy does not improve the outcome of ovarian cancer. In addition to the usual reasons for pregnancy termination, some factors that should be considered in patients with ovarian cancer include:</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the patient is willing to assume a possible risk of fetal toxicity or complications from ovarian cancer treatment during pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient's prognosis and ability to care for the offspring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of ovarian cancer treatment on future fertility.</p><p></p><p class="headingAnchor" id="H613402297"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119051.html" rel="external">"Society guideline links: Ovarian and fallopian tube disease"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Approximately 0.05 to 2.4 percent of pregnancies are complicated by an adnexal mass, and approximately 1 to 6 percent of these masses are malignant. (See <a class="local">'Prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Most pregnant patients with an adnexal mass are asymptomatic and the mass is discovered incidentally either on obstetric ultrasound examination or at cesarean birth. Symptoms of ovarian cancer include abdominal or back pain, constipation, abdominal swelling, and urinary symptoms, which are also almost universally present during normal pregnancies. (See <a class="local">'Patient presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor markers</strong> – An unexplained elevation in some maternal serum analytes  (<a class="graphic graphic_table graphicRef55817" href="/z/d/graphic/55817.html" rel="external">table 1</a>), obtained during screening for neural tube defects or Down syndrome, can be a sign of an ovarian germ cell tumor. (See <a class="local">'Patient presentation'</a> above and <a class="local">'Tumor markers in ovarian malignancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of masses</strong> – Most adnexal masses identified in pregnant patients are benign simple cysts &lt;5 cm in diameter and are functional ovarian cysts, either follicular or corpus luteum cysts, that occur as part of the normal physiological function of the ovary. Approximately 70 percent of all adnexal cystic masses detected in the first trimester spontaneously resolve by the early part of the second trimester. The majority of persistent adnexal masses ≥5 cm in diameter are dermoids. Up to 10 percent of adnexal masses that persist during pregnancy are malignant. (See <a class="local">'Types of adnexal masses in pregnant patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Definitive diagnosis can only be made by resecting the ovarian neoplasm for pathologic examination. However, some benign ovarian masses, including follicular or corpus luteal cysts, endometriomas, and mature teratomas (dermoid), have characteristic sonographic features and the diagnosis is reasonably certain without surgical exploration. Pregnancy-associated ovarian tumors should be evaluated by a pathologist skilled in reading the pathologic findings in the context of the ongoing pregnancy, and the pathologist should be informed of the coexistent pregnancy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest surgical resection rather than expectant management of asymptomatic masses present after the first trimester that are (1) &gt;10 cm in diameter (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) or (2) solid or containing solid and cystic areas or papillary areas or septae (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). These findings increase the likelihood of malignancy, and it is desirable to diagnose malignancy, if present, at an early stage. In addition, resection of large adnexal masses reduces the risk of complications (eg, adnexal torsion, rupture, obstruction of labor). However, we suggest expectant management of asymptomatic corpus luteal cysts, endometriomas, and mature teratomas (dermoid) during pregnancy if the diagnosis is reasonably certain based on the sonographic characteristics (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patient selection for surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Removal of the corpus luteum prior to eight weeks of gestation requires postoperative <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> supplementation. (See <a class="local">'Management of corpus luteum'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of surgery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the preoperative imaging and intraoperative gross findings are both consistent with a benign diagnosis, we suggest cystectomy rather than salpingo-oophorectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If the mass is &gt;10 cm, it may not be technically feasible to perform an ovarian cystectomy. If the mass is solid, has surface excrescences, is associated with ascites, or has other features suggesting malignancy, then ipsilateral salpingo-oophorectomy is appropriate. The mass should be sent for frozen section. Resection of the contralateral ovary should not be performed unless bilateral disease is identified. All suspicious lesions should be biopsied. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adequate surgical staging is important for stage I cancers, as many of these neoplasms are adequately treated with surgery alone. Surgical staging (eg, sampling of lymph nodes) is less critical in advanced disease (eg, stage IIIB/C disease), as most of these tumors require chemotherapy. If a metastatic ovarian cancer is identified, the extent of surgical cytoreduction involves individual judgment, balancing the extent of surgery with the expected benefit. Before delivery, we leave as much of the reproductive tract in situ as possible, as patients with advanced-stage epithelial ovarian cancer can undergo completion of debulking of the reproductive organs following delivery. (See <a class="local">'Surgery'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schmeler KM, Mayo-Smith WW, Peipert JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005; 105:1098.</a></li><li><a class="nounderline abstract_t">Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol 2001; 184:1504.</a></li><li><a class="nounderline abstract_t">Webb KE, Sakhel K, Chauhan SP, Abuhamad AZ. Adnexal mass during pregnancy: a review. Am J Perinatol 2015; 32:1010.</a></li><li><a class="nounderline abstract_t">Aggarwal P, Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155:119.</a></li><li><a class="nounderline abstract_t">Palmer J, Vatish M, Tidy J. Epithelial ovarian cancer in pregnancy: a review of the literature. BJOG 2009; 116:480.</a></li><li><a class="nounderline abstract_t">Shim MH, Mok CW, Chang KH, et al. Clinical characteristics and outcome of cancer diagnosed during pregnancy. Obstet Gynecol Sci 2016; 59:1.</a></li><li><a class="nounderline abstract_t">Giuntoli RL 2nd, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clin Obstet Gynecol 2006; 49:492.</a></li><li><a class="nounderline abstract_t">Machado F, Vegas C, Leon J, et al. Ovarian cancer during pregnancy: analysis of 15 cases. Gynecol Oncol 2007; 105:446.</a></li><li><a class="nounderline abstract_t">Baser E, Erkilinc S, Esin S, et al. Adnexal masses encountered during cesarean delivery. Int J Gynaecol Obstet 2013; 123:124.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.</a></li><li><a class="nounderline abstract_t">Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221.</a></li><li><a class="nounderline abstract_t">Yen CF, Lin SL, Murk W, et al. Risk analysis of torsion and malignancy for adnexal masses during pregnancy. Fertil Steril 2009; 91:1895.</a></li><li><a class="nounderline abstract_t">Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44:151.</a></li><li><a class="nounderline abstract_t">Chiang G, Levine D. Imaging of adnexal masses in pregnancy. J Ultrasound Med 2004; 23:805.</a></li><li><a class="nounderline abstract_t">Bakri YN, Ezzat A, Akhtar, et al. Malignant germ cell tumors of the ovary. Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol 2000; 90:87.</a></li><li><a class="nounderline abstract_t">Kumar S, Shah JP, Bryant CS, et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 2008; 110:125.</a></li><li><a class="nounderline abstract_t">Young RH, Dudley AG, Scully RE. Granulosa cell, Sertoli-Leydig cell, and unclassified sex cord-stromal tumors associated with pregnancy: a clinicopathological analysis of thirty-six cases. Gynecol Oncol 1984; 18:181.</a></li><li><a class="nounderline abstract_t">Mooney J, Silva E, Tornos C, Gershenson D. Unusual features of serous neoplasms of low malignant potential during pregnancy. Gynecol Oncol 1997; 65:30.</a></li><li><a class="nounderline abstract_t">Wang PH, Chao HT, Yuan CC, et al. Ovarian tumors complicating pregnancy. Emergency and elective surgery. J Reprod Med 1999; 44:279.</a></li><li><a class="nounderline abstract_t">Lee GS, Hur SY, Shin JC, et al. Elective vs. conservative management of ovarian tumors in pregnancy. Int J Gynaecol Obstet 2004; 85:250.</a></li><li><a class="nounderline abstract_t">Leiserowitz GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv 2006; 61:463.</a></li><li><a class="nounderline abstract_t">Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol 1999; 93:585.</a></li><li><a class="nounderline abstract_t">Testa AC, Mascilini F, Quagliozzi L, et al. Management of ovarian masses in pregnancy: patient selection for interventional treatment. Int J Gynecol Cancer 2021; 31:899.</a></li><li><a class="nounderline abstract_t">Montes de Oca MK, Dotters-Katz SK, Kuller JA, Previs RA. Adnexal Masses in Pregnancy. Obstet Gynecol Surv 2021; 76:437.</a></li><li><a class="nounderline abstract_t">Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999; 181:19.</a></li><li><a class="nounderline abstract_t">Yakasai IA, Bappa LA. Diagnosis and management of adnexal masses in pregnancy. J Surg Tech Case Rep 2012; 4:79.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol 2016; 128:e210.</a></li><li><a class="nounderline abstract_t">Hoffman MS, Sayer RA. Adnexal masses in pregnancy. OBG Management 2007; 19:27.</a></li><li><a class="nounderline abstract_t">Zanetta G, Mariani E, Lissoni A, et al. A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy. BJOG 2003; 110:578.</a></li><li><a class="nounderline abstract_t">Sherard GB 3rd, Hodson CA, Williams HJ, et al. Adnexal masses and pregnancy: a 12-year experience. Am J Obstet Gynecol 2003; 189:358.</a></li><li><a class="nounderline abstract_t">Agarwal N, Parul, Kriplani A, et al. Management and outcome of pregnancies complicated with adnexal masses. Arch Gynecol Obstet 2003; 267:148.</a></li><li><a class="nounderline abstract_t">Caspi B, Levi R, Appelman Z, et al. Conservative management of ovarian cystic teratoma during pregnancy and labor. Am J Obstet Gynecol 2000; 182:503.</a></li><li><a class="nounderline abstract_t">Perera DS, Prabhakar HB. Imaging of the adnexal mass. Clin Obstet Gynecol 2015; 58:28.</a></li><li><a class="nounderline abstract_t">Hoffman MS. Primary ovarian carcinoma during pregnancy. Clin Consul Obstet Gynecol 1995; 7:237.</a></li><li><a class="nounderline abstract_t">Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol 2019; 30:1601.</a></li><li><a class="nounderline abstract_t">Thomassin-Naggara I, Fedida B, Sadowski E, et al. Complex US adnexal masses during pregnancy: Is pelvic MR imaging accurate for characterization? Eur J Radiol 2017; 93:200.</a></li><li><a class="nounderline abstract_t">Telischak NA, Yeh BM, Joe BN, et al. MRI of adnexal masses in pregnancy. AJR Am J Roentgenol 2008; 191:364.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Obstetric Practice. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol 2004; 104:647.</a></li><li><a class="nounderline abstract_t">Harvey EB, Boice JD Jr, Honeyman M, Flannery JT. Prenatal x-ray exposure and childhood cancer in twins. N Engl J Med 1985; 312:541.</a></li><li><a class="nounderline abstract_t">Frederiksen MC, Casanova L, Schink JC. An elevated maternal serum alpha-fetoprotein leading to the diagnosis of an immature teratoma. Int J Gynaecol Obstet 1991; 35:343.</a></li><li><a class="nounderline abstract_t">Nawa A, Obata N, Kikkawa F, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184:1182.</a></li><li><a class="nounderline abstract_t">Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol 1999; 72:123.</a></li><li><a class="nounderline abstract_t">Horbelt D, Delmore J, Meisel R, et al. Mixed germ cell malignancy of the ovary concurrent with pregnancy. Obstet Gynecol 1994; 84:662.</a></li><li><a class="nounderline abstract_t">Buller RE, Darrow V, Manetta A, et al. Conservative surgical management of dysgerminoma concomitant with pregnancy. Obstet Gynecol 1992; 79:887.</a></li><li><a class="nounderline abstract_t">Demir SC, Evruke C, Ozgunen FT, et al. Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Saudi Med J 2006; 27:1015.</a></li><li><a class="nounderline abstract_t">Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.</a></li><li><a class="nounderline abstract_t">Luisi S, Florio P, Reis FM, Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update 2005; 11:123.</a></li><li><a class="nounderline abstract_t">Moore RG, Miller MC, Eklund EE, et al. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol 2012; 206:349.e1.</a></li><li><a class="nounderline abstract_t">Gucer F, Kiran G, Canaz E, et al. Serum human epididymis protein 4 can be a useful tumor marker in the differential diagnosis of adnexal masses during pregnancy: a pilot study. Eur J Gynaecol Oncol 2015; 36:406.</a></li><li><a class="nounderline abstract_t">Ball E, Waters N, Cooper N, et al. Evidence-Based Guideline on Laparoscopy in Pregnancy: Commissioned by the British Society for Gynaecological Endoscopy (BSGE) Endorsed by the Royal College of Obstetricians &amp; Gynaecologists (RCOG). Facts Views Vis Obgyn 2019; 11:5.</a></li><li><a class="nounderline abstract_t">Rajendran S, Hollingworth J, Scudamore I. Endodermal sinus tumour of the ovary in pregnancy. Eur J Gynaecol Oncol 1999; 20:272.</a></li><li><a class="nounderline abstract_t">Méndez LE, Mueller A, Salom E, González-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol 2003; 102:1200.</a></li><li><a class="nounderline abstract_t">Picone O, Lhommé C, Tournaire M, et al. Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol 2004; 94:600.</a></li><li><a class="nounderline abstract_t">Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 2001; 83:599.</a></li><li><a class="nounderline abstract_t">Ferrandina G, Distefano M, Testa A, et al. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review. Gynecol Oncol 2005; 97:693.</a></li><li><a class="nounderline abstract_t">Csapo AI, Pulkkinen MO, Ruttner B, et al. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol 1972; 112:1061.</a></li><li><a class="nounderline abstract_t">Csapo AI, Pulkkinen MO, Wiest WG. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 1973; 115:759.</a></li><li><a class="nounderline abstract_t">Grimm D, Woelber L, Trillsch F, et al. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer 2014; 50:963.</a></li><li><a class="nounderline abstract_t">Zhao XY, Huang HF, Lian LJ, Lang JH. Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature. Int J Gynecol Cancer 2006; 16:8.</a></li><li><a class="nounderline abstract_t">Cairncross ZF, Shack L, Nelson G, et al. Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum. JAMA Oncol 2023; 9:791.</a></li><li><a class="nounderline abstract_t">Johansson ALV, Fredriksson I, Mellemkjaer L, et al. Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018. Eur J Cancer 2021; 155:106.</a></li><li><a class="nounderline abstract_t">Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.</a></li></ol></div><div id="topicVersionRevision">Topic 3201 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863550" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Adnexal masses in pregnancy: surgery compared with observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408874" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26007316" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adnexal mass during pregnancy: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21194826" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ovarian tumours in pregnancy: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250360" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epithelial ovarian cancer in pregnancy: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866029" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical characteristics and outcome of cancer diagnosed during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885656" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evaluation and management of adnexal masses during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292456" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ovarian cancer during pregnancy: analysis of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24008309" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Adnexal masses encountered during cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187051" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Frequency of symptoms of ovarian cancer in women presenting to primary care clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17154394" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Development of an ovarian cancer symptom index: possibilities for earlier detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18359024" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk analysis of torsion and malignancy for adnexal masses during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17364691" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tumor markers in biological fluids associated with pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15244305" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Imaging of adnexal masses in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10767517" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Malignant germ cell tumors of the ovary. Pregnancy considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571705" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6735262" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Granulosa cell, Sertoli-Leydig cell, and unclassified sex cord-stromal tumors associated with pregnancy: a clinicopathological analysis of thirty-six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9103387" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Unusual features of serous neoplasms of low malignant potential during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202748" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ovarian tumors complicating pregnancy. Emergency and elective surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15145260" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Elective vs. conservative management of ovarian tumors in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16787549" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Managing ovarian masses during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10214838" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predictors of persistence of adnexal masses in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33172924" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of ovarian masses in pregnancy: patient selection for interventional treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34324696" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adnexal Masses in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741580" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Diagnosis and management of adnexal masses in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776072" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adnexal masses in pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798475" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520194" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adnexal masses and pregnancy: a 12-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580154" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management and outcome of pregnancies complicated with adnexal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10739498" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Conservative management of ovarian cystic teratoma during pregnancy and labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25608251" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Imaging of the adnexal mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary ovarian carcinoma during pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31435648" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28668416" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Complex US adnexal masses during pregnancy: Is pelvic MR imaging accurate for characterization?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647903" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : MRI of adnexal masses in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339791" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3969117" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prenatal x-ray exposure and childhood cancer in twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718791" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An elevated maternal serum alpha-fetoprotein leading to the diagnosis of an immature teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11349186" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prognostic factors of patients with yolk sac tumors of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9889045" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205440" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mixed germ cell malignancy of the ovary concurrent with pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1565399" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Conservative surgical management of dysgerminoma concomitant with pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16830022" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637488" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Granulosa cell tumor of the ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618291" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22301440" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26390692" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Serum human epididymis protein 4 can be a useful tumor marker in the differential diagnosis of adnexal masses during pregnancy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31695854" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evidence-Based Guideline on Laparoscopy in Pregnancy: Commissioned by the British Society for Gynaecological Endoscopy (BSGE) Endorsed by the Royal College of Obstetricians&amp;Gynaecologists (RCOG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10475120" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Endodermal sinus tumour of the ovary in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607056" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297214" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11733979" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863184" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5017636" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4688578" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of luteectomy and progesterone replacement therapy in early pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462638" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical management of epithelial ovarian cancer during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16445603" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37022714" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34371441" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cancer survival in women diagnosed with pregnancy-associated cancer: An overview using nationwide registry data in Sweden 1970-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029418" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
